Key result
Loss of SOCS3 in cardiomyocytes aggravated DOCA-salt-induced cardiac dysfunction, hypertrophy, fibrosis, and inflammation, whereas AAV9-SOCS3 injection significantly reduced these effects.
Why the study?
Does SOCS3 expression modulate DOCA-salt-induced cardiac remodeling and inflammation in mice?
Does SOCS3 expression modulate DOCA-salt-induced cardiac remodeling and inflammation in mice?
Loss of SOCS3 in cardiomyocytes promotes DOCA-salt-induced cardiac remodeling and inflammation, highlighting it as a potential therapeutic target for hypertensive heart disease.
Refinement for "Verdict clause" style:* Highlights SOCS3 as a potential.
BACKGROUND/AIMS: Cardiac remodeling is a critical pathogenetic process leading to heart failure. Suppressor of cytokine signaling-3 (SOCS3) is demonstrated as a key negative regulator of the gp130 receptor to inhibit cardiac hypertrophy. However, the role of SOCS3 in deoxycorticosterone-acetate (DOCA)-salt-induced cardiac remodeling remains unclear. METHODS: Cardiac-specific SOCS3 knockout (SOCS3cKO) and wild-type (WT) C57BL/6J mice were subjected to uninephrectomy and DOCA-salt for 3 weeks. The effect of SOCS3 on cardiac remodeling and inflammation was evaluated by histological analysis. Gene and protein levels were measured by real-time PCR and immunoblotting analysis. RESULTS: After DOCA-salt treatment, the expression of SOCS3, activation of gp130/JAK/STAT3, cardiac dysfunction and fibrosis in DOCA-salt mice were significantly elevated, which were markedly attenuated by eplerenone, a specific mineralocorticoid receptor (MR) blocker. Moreover, DOCA-salt-induced cardiac dysfunction, hypertrophy, fibrosis and inflammation were aggravated in SOCS3cKO mice, but were significantly reduced in AAV9-SOCS3-injected mice. These effects were mostly associated with activation of gp130/STAT3/AKT/ERK1/2, TGF-β/Smad2/3 and NF-κB signaling pathways. CONCLUSIONS: Our data demonstrate that loss of SOCS3 in cardiomyocytes promotes DOCA-salt-induced cardiac remodeling and inflammation, and it may be a novel potential therapeutic target for hypertensive heart disease.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2018) studied DOCA-salt-induced cardiac remodeling. Cardiac-specific SOCS3 knockout vs. Wild-type mice was evaluated on Cardiac dysfunction, hypertrophy, fibrosis and inflammation. Loss of SOCS3 in cardiomyocytes aggravated DOCA-salt-induced cardiac dysfunction, hypertrophy, fibrosis, and inflammation, whereas AAV9-SOCS3 injection significantly reduced these effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: